Cargando…
Pitavastatin: evidence for its place in treatment of hypercholesterolemia
Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, are the most potent pharmacologic agents for lowering total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C). They have become an accepted standard of care in the treatment of patients with known atherosclerotic...
Autor principal: | Alagona, Peter |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3065553/ https://www.ncbi.nlm.nih.gov/pubmed/21468365 http://dx.doi.org/10.2147/CE.S8008 |
Ejemplares similares
-
Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia
por: Sasaki, Jun
Publicado: (2010) -
Benefit–risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients
por: Chamberlin, Kevin W, et al.
Publicado: (2015) -
Place of pitavastatin in the statin armamentarium: promising evidence for a role in diabetes mellitus
por: Kawai, Yasuyuki, et al.
Publicado: (2011) -
Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe
por: Harada-Shiba, Mariko, et al.
Publicado: (2018) -
Comparison of effects of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with hypercholesterolemia
por: Mita, Tomoya, et al.
Publicado: (2013)